<DOC>
	<DOCNO>NCT02896790</DOCNO>
	<brief_summary>The use oral targeted therapy draw new medical management also new practice patient ( compliance ) , family healthcare professional [ 1,2 ] . These therapy sometimes heavy toxicity : side effect identify , treat , patient learn manage . This situation underline importance therapeutic education accompany `` learn '' [ 3 ] . Nevertheless , France , therapeutic educational program , build accord `` standard '' therapeutic education ( TE ) , still rare cancer research [ 4 ] . In May 2012 , therapeutic educational program patient develop oncology department Teaching Hospital Bordeaux multidisciplinary team . This program , dedicate metastatic renal cancer patient treat oral targeted therapy , becomes object research : MODAP ( action-research ) .</brief_summary>
	<brief_title>From Model Adaptation Therapeutic Education Program ( TEP ) Cancer Research</brief_title>
	<detailed_description>At diagnosis , 25 30 % renal cancer patient present metastatic disease . The prognosis remain dark spite advent target therapy 2007 . Actually , use oral target therapy , time carry outpatient basis ( sunitinib particular ) , draw new medical management also new practice patient ( compliance ) , family healthcare professional [ 1,2 ] . These therapy sometimes heavy toxicity : side effect identify , treat , patient learn manage . This situation underline importance therapeutic education accompany `` learn '' [ 3 ] . Nevertheless , therapeutic educational program , build accord `` standard '' therapeutic education ( TE ) , still rare cancer research [ 4 ] : multiplicity pathology ( cancer , cancer ) , multiplicity patient ' experience , difficulty implementation ? In May 2012 , front experience tell patient professional context metastatic renal cancer , member oncology department Teaching Hospital Bordeaux , therapeutic educational Federation , Coordination Cancer Centre ( 3C ) , anthropologist , expert patient patient 's association develop therapeutic educational program patient [ current approval ] . This program , build model TE France , become object research : MODAP ( action-research ) .</detailed_description>
	<criteria>Age = 18 year old Metastatic Renal cancer ( carcinoma clear cell subcategories ) Indication first line treatment therapy target Sutent Â© General WHO 02 state Life expectancy = 12 week Agree participate MODAP ( Therapeutic Education ) History cancer History severe psychiatric affection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Oral Therapy</keyword>
	<keyword>Compliance</keyword>
	<keyword>Anthropology</keyword>
	<keyword>Psychology</keyword>
</DOC>